Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Financial Results

Viking Therapeutics Shares Jump 18% in 12 Days Since Financial Results

Viking Therapeutics Reports Q3-26 Net Loss of $183.19M as Clinical R&D Accelerates

+18.69% in 12 days $25.36 when we broke this story → $30.10 peak on 10 Nov 2026

Viking Therapeutics saw its quarterly net loss expand to $183.19 million in Q3-26 as it ramped up research and development for its metabolic drug candidates. The company remains in a pre-revenue clinical stage, supported by a cash position of $677.6 million.

Microscope, lab, research, medical. Stock photo illustrating Viking Therapeutics' financial results story.
Viking Therapeutics, Inc. · Photo: PublicDomainPictures / Pixabay
Results at a glance · $ Million
Metric Q3-26Q3-25
Revenue 0.000.00
Net Income -183.19-90.79
Diluted EPS -1.55-0.81
Net Income YoY
-101.8%

Key highlights

  • Net loss widened by 101.8% year-over-year to $183.19 million in Q3-26
  • Diluted loss per share increased to $1.55 compared to $0.81 in Q3-25
  • Research and development expenses totaled $432.7 million for the first nine months of 2026
  • Company ended the period with $677.6 million in cash and cash equivalents
  • Projected quarterly cash burn guided at approximately $100 million moving forward

How the Period Went

Viking Therapeutics reported zero revenue for the third quarter of 2026, maintaining its status as a clinical-stage biotechnology firm with no commercial products. The net loss for the quarter expanded to $183.19 million, a significant increase from the $90.79 million loss recorded during the same period in 2025. This results in a year-over-year net income decline of 101.8%. On a per-share basis, the diluted loss reached $1.55, compared to $0.81 in the prior year. The widening deficit reflects a strategic pivot toward intensive late-stage clinical trials for its primary metabolic and endocrine candidates.

Margins and Profitability

Profitability metrics remain negative as Viking prioritizes R&D over short-term earnings. For the first nine months of 2026, research and development expenses reached $432.7 million, contributing to a total nine-month net loss of $469.5 million. Management guidance provided via MarketBeat on October 28, 2026, anticipates an average quarterly cash burn of roughly $100 million. Despite these losses, the company bolstered its liquidity through public offerings and convertible senior notes, concluding the quarter with $677.6 million in cash. This capital cushion is intended to fund the upcoming high-cost Phase 3 extension studies planned for early 2027.

Business Overview

  • Clinical-stage biopharmaceutical developer focused on novel metabolic therapies
  • Lead program VK2735 is a dual GLP-1/GIP receptor agonist for obesity treatment
  • Developing VK3019, a dual amylin/calcitonin receptor agonist (DACRA)
  • Zero order backlog as of September 30, 2026, according to GuruFocus data
  • Targeting Phase 1 completion of VK3019 by year-end 2026 per company updates
  • Expected initiation of VANQUISH Phase 3 studies for VK2735 in Q1 2027

Financial Context

The current financial results arrive during a period of market volatility for the company. Viking’s market capitalization stands at approximately $2.96 billion, with the stock trading at $25.36. Technical indicators show a Relative Strength Index (RSI) of 40.5, positioning the equity in neutral territory after a quarterly price decline of 27.27%. The 23.22% drop over the last month aligns with broader biotech sector fluctuations as investors weigh high cash burn rates against the long-term potential of weight-loss drug pipelines. The company's recent capital raises have secured the runway necessary to navigate these pre-commercial phases.

Viking Therapeutics, Inc. share price · last month
Line chart of Viking Therapeutics, Inc.'s share price over the last month, from $25.05 on 19 Oct → $26.80 on 16 Nov; our story on 29 Oct at $25.36.

Up 5.7% since our story on 29 Oct: $25.36 when we broke it → $26.80 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$25.05
20 Oct$26.71
21 Oct$26.38
22 Oct$25.83
23 Oct$24.40
26 Oct$24.21
27 Oct$24.89
28 Oct$25.36
29 Oct$26.86
30 Oct$27.28
2 Nov$26.83
3 Nov$26.09
4 Nov$27.97
5 Nov$25.79
6 Nov$26.84
9 Nov$28.99
10 Nov$28.66
11 Nov$28.44
12 Nov$27.58
13 Nov$29.22
16 Nov$26.80

Industry Landscape

Viking Therapeutics operates in the competitive metabolic therapeutic space, currently dominated by established GLP-1 providers. While larger peers report surging commercial sales, Viking competes on next-generation delivery and dual-agonist efficacy. According to company announcements via StockTitan, the expected Q1 2027 initiation of Phase 3 studies for subcutaneous VK2735 will be a critical sector event. Industry demand for obesity treatments remains high, but clinical-stage firms like Viking face pressure to deliver differentiated data in a crowded field of amylin and GIP receptor agonists. The completion of the VK3019 study by year-end will be an important indicator of pipeline breadth.

Recent quarters and guidance
DateAnnouncementAmount
28 Oct 2026Q3 2026 net lossSource: prnewswire.com$183.2 Million
29 Jul 2026Q2 2026 net lossSource: prnewswire.com$128.0 Million
29 Apr 2026Q1 2026 net lossSource: prnewswire.com$158.3 Million
11 Feb 2026Q4 2025 net lossSource: prnewswire.com$157.7 Million
22 Oct 2025Q3 2025 net lossSource: investing.com$90.8 Million
23 Jul 2025Q2 2025 net lossSource: SEC filing$65.6 Million
Viking Therapeutics, Inc. · financial snapshot
Share price$25.36
Market cap$3.0B
1-month price change-23.22%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Viking Therapeutics, Inc. announcing its third quarter 2026 financial results.

Read the filing ↗

Track Viking Therapeutics, Inc. live

Get the next Viking Therapeutics, Inc. SEC filing seconds after it lands.

More in Results & Earnings

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.